{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"ELAINEIII","nct_id":"NCT05696626","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=elaineiii-nct05696626. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ELAINEIII","arms":[{"description":"Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.","label":"Treatment","type":"EXPERIMENTAL"},{"description":"Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.","label":"Reference Therapy","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2028-04","type":"ESTIMATED"},"conditions":["Metastatic Breast Cancer"],"enrollment":{"count":600,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Lasofoxifene in combination with abemaciclib","otherNames":[],"type":"DRUG"},{"name":"Fulvestrant in combination with abemaciclib","otherNames":[],"type":"DRUG"}],"last_update":"2026-06-22","lead_sponsor":"LeonaBio","official_title":"An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival (PFS)","timeFrame":"Within approximately 3 years"}],"references":[{"citation":"Goetz MP, Wander SA, Bachelot T, de Nonneville A, Gal-Yam EN, Sammons SL, Shen S, Twelves C, Boruta G, Portman DJ, Damodaran S. ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, ESR1-mutated, metastatic breast cancer. Future Oncol. 2025 May;21(11):1317-1324. doi: 10.1080/14796694.2025.2481825. Epub 2025 Apr 13.","pmid":"40222048","type":"DERIVED"}],"start_date":{"date":"2023-10-31","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation","url":"https://clinicaltrials.gov/study/NCT05696626"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/elaineiii-nct05696626"}